anti-PD-1/PD-L1 therapiesThe Ohio State University Comprehensive Cancer CenterMerkel cell carcinomaOSUCCCPelotonia Institute for Immuno-OncologyMCCNational Institutes of HealthNIH
…ltration, MCC tumors often evade immune-mediated killing. While anti-PD-1/PD-L1 therapies are efficacious, MCC patients resistant or relapsing after immu…